← Human Trials & Peer-Reviewed Studies
The effects of concurrent alpha-linolenic acid, L-carnitine supplementation on clinical symptoms, mental health, and quality of life in women with migraine: a randomized, triple-blind, placebo-controlled trial
Plain-language guide to PMID 40082970 (2025): double-blind randomized controlled trial study of L-Carnitine in 80 women, migraine.
Key Facts
- PMID
- 40082970
- Journal
- Nutrition journal
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Golpour-Hamedani S et al. (6 authors)
- DOI
- 10.1186/s12937-025-01107-7
What This Study Did, in Plain Language
What Was Tested
Researchers studied L-Carnitine in the context of migraine in this randomized controlled trial publication.
Migraine, as a widespread neurological condition, substantially impacts quality of life, particularly among women.
Therefore, this study aimed to explore the potential effects of alpha-linolenic acid (ALA) and L-carnitine co-supplementation on migraine symptoms, mental health, and life quality in women with migraine.
Who Took Part
The study group was 80 women.
The age groups tagged for this paper are young adults, adults and middle-aged adults, women only.
Migraine characteristics, mental health parameters, and quality of life measures were assessed at baseline and study end.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this L-Carnitine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the women nor the staff measuring them knew who was on L-Carnitine, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the L-Carnitine group a baseline to be compared against.
What Was Measured
PubMed files the paper under topics including Quality of Life, Carnitine, Migraine Disorders, alpha-Linolenic Acid, Dietary Supplements and Mental Health.
Author keywords: L-carnitine.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of L-Carnitine in 80 women in people with migraine.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2025 (Nutrition journal), a journal based in England.
More context: the L-Carnitine compound page, Migraine research.
Our Notes on the Compound
L-Carnitine: An amino acid derivative that carries fatty acids into mitochondria for energy production.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.